DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Boeing, Norfolk Southern, Nvidia & more
▼ + stars: | 2024-04-09 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

BlackBerry — BlackBerry shares popped more than 9% after the company announced a partnership with Advanced Micro Devices on robotics systems. Neogen Corp — The food safety stock shed 9% after the company reported a surprise loss of 1 cent per share. The company also trimmed its previous guidance, saying it now expects revenue to range between $920 million and $910 million for the full year. Norfolk Southern announced that it reached a $600 million settlement related to its derailment in East Palestine. Nvidia — Shares fell more than 2%, putting the chipmaker on track for its fifth losing session in six.

Persons: Tilray, FactSet, Goldman Sachs, Molson Coors, Molson, — CNBC's Michelle Fox, Sarah Min, Pia Singh, Yun Li Organizations: Moderna, Reuters, Merck, Boeing, New York Times, Google, American Eagle Outfitters, JPMorgan, Eagle Outfitters, Bank of America, EV, Molson, Pfizer, Neogen Corp, Norfolk Southern, Nvidia —, Netflix Locations: East Palestine

☆ Stocks making the biggest moves premarket: American Eagle Outfitters, Ally Financial, Molson Coors Beverage and more
▼ + stars: | 2024-04-09 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Check out the companies making headlines before the bell: American Eagle Outfitters — Shares popped 4% following an upgrade by JPMorgan to overweight from neutral. Freeport-McMoRan — Shares jumped 1.9% after Bank of America upgraded the American mining company to buy from neutral, saying it has "blue chip copper exposure." Molson Coors — Shares gained 1.9% after Goldman Sachs upgraded the brewing company to buy, saying the company can benefit as it expands its shelf space in retailers. Ally Financial — The financial services company added nearly 2% after being upgraded to buy from neutral at Bank of America. The bank's analysts believe Ally Financial may see higher earnings than anticipated, less earnings volatility and that its potential credit leverage may be underestimated.

Persons: Molson, Goldman Sachs, Ally, — CNBC's Michelle Fox Organizations: Eagle Outfitters, JPMorgan, Bank of America, Molson Coors —, Ally, Google, Pfizer Locations: Freeport

☆ Record levels of funding propel Denver-Boulder to the top of the life sciences market
▼ + stars: | 2024-04-08 | by ( Chris Dilella | ) www.cnbc.com time to read: +7 min

The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and technologies. Life sciences research aims to understand living things, from cells to our planet, to improve health, food and the environment. Founded in 2003, the Bioscience Association supports the growth of life sciences, with a focus on access to capital, education, networking and more. A recent CBRE report found Denver-Boulder to be the top U.S. life sciences real estate market, fueled by record investment from venture capitalists and the National Institutes of Health. Entrepreneurial successThe recent surge in venture capital flowing into Denver-Boulder builds on the area's proven track record of success over the past several decades.

Persons: Tim Schoen, BioMed, Schoen, Elyse Blazevich, Kevin Koch, Koch, Edgewise, We've, Dan LaBarbera, LaBarbera, Dr Organizations: BioMed, CNBC, Blackstone, Flatiron, Enveda Biosciences, Denver, Boulder, Colorado Bioscience Association, Bioscience Association, National Institutes of Health, U.S, Pfizer, Therapeutics, University of Colorado, Edgewise Therapeutics, Research, University of Colorado's Anschutz Medical, Center, Drug, Center for Drug, for Drug, Anschutz Medical Locations: CNBC's, Denver, Boulder, Diego, Boulder , Colorado, San Diego, San Francisco, Seattle, Boston, Cambridge, Massachusetts, Aurora, Rocky, Colorado, Boulder ., Denver's

☆ Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
▼ + stars: | 2024-04-05 | by ( ) edition.cnn.com time to read: +3 min

Sanofi has reached an agreement in principle to settle 4,000 US lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi still faces about 20,000 lawsuits over Zantac in Delaware state court. That judge concluded that the opinions of the plaintiffs’ expert witnesses that Zantac can cause cancer were not supported by sound science. “We are pushing forward aggressively against GSK and Boehringer Ingelheim and are preparing for multiple trials in California state court this year,” Moore said. Lawsuits began piling up from people who said they developed cancer after taking Zantac.

Persons: Sanofi, “ Sanofi, Boehringer, Boehringer Ingelheim, Jennifer Moore, Brent Wisner, ” Moore, Zantac, ranitidine Organizations: Court, Sanofi, GSK, Pfizer, Boehringer, US Food and Drug Administration Locations: Delaware, Zantac, Wilmington, Florida, California

☆ US scientists are leaving academia. That’s bad news for drug companies
▼ + stars: | 2024-04-01 | by ( Eva Rothenberg | ) edition.cnn.com time to read: +5 min

“Science postdocs perform the science,” Donna Ginther, an economist who studies the science labor market at the University of Kansas, told CNN. Biomedical companies take scientific contributions and, over time, aggregate them into a commercial product. Building on the discovery of mRNA in the 1960’s, the technology behind an mRNA vaccine for humans was in development for decades before the Covid-19 vaccine was first administered in 2020. By using that technology to develop their mRNA vaccines for Covid-19, pharmaceutical companies like Pfizer and Moderna made a windfall in profits. “That’s how they make money is through commercialization: they have a product, which they then patent and sell.”Why are scientists leaving academic labs?

Persons: postdocs, Donna Ginther, “ They’re, Michael Ciaglo, ”, “, Nobel, Dr, Katalin Kariko, ” Ginther, they’re, Ginther Organizations: New, New York CNN —, National Institutes of Health, NIH, National Science Foundation, University of Kansas, CNN, ”, Pfizer, Moderna, Wired Magazine, NSF, World Health Organization Locations: New York, United States, Denver , Colorado, Europe, Alzheimer’s

☆ Cramer's Lightning Round: Leidos is a winner
▼ + stars: | 2024-03-28 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Core & Main's year-to-date stock performance. Stock Chart Icon Stock chart icon Pfizer's year-to-date stock performance. Stock Chart Icon Stock chart icon SFL's year-to-date stock performance. Stock Chart Icon Stock chart icon Leidos' year-to-date stock performance. Stock Chart Icon Stock chart icon KLA's year-to-date stock performance.

Persons: it's, They've, Leidos, that's, Mike Wirth's, I'm, It's Organizations: Pfizer, Chevron

☆ Calls of the Day: Bank of America, Oracle, Abbvie and Pfizer
▼ + stars: | 2024-03-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Bank of America, Oracle, Abbvie and PfizerThe Investment Committee debates the latest calls of the day and how to trade them.

Organizations: Bank of America, Oracle, Abbvie, Pfizer

☆ Forget Nvidia: Here are four stocks one investor is betting on instead
▼ + stars: | 2024-03-26 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +6 min

Instead, the veteran wealth manager is now looking for stocks in growth sectors that look "reasonably valued." He said the pharmaceutical, real estate, energy and financial sectors were on his radar, and named four stocks that stand out. Pfizer Pharmaceutical company Pfizer — well known for its Covid-19 vaccine — is betting on cancer drugs , following its $43 billion acquisition of Seagen last year . Over the last 12 months, shares of Comerica are up around 28%, although they are down 7.5% year-to-date. According to Factset data, analysts' average price target on the stock is $59.45, giving it around 15% potential upside.

Persons: David Dietze, Dietze, —, Schlumberger —, Dietze's, SLB Organizations: Nvidia, Wealth Management, Pfizer Pharmaceutical, Pfizer, CNBC Pro, Schlumberger, Comerica Locations: Seagen, U.S, SLB, Canada

☆ Moderna says new Covid vaccine showed stronger immune response than current shot in study
▼ + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Tuesday said a new version of its Covid vaccine triggered a stronger immune response against the virus than its current shot in a late-stage trial. Moderna's current Covid vaccine, known as Spikevax, is its only commercially available product. The biotech company's new shot could offer a longer shelf life and easier storage than its Covid vaccine. The company will accomplish that by shortening the length of the mRNA strand in the vaccine, Moderna previously told CNBC. The company's shot against respiratory syncytial virus is expected to win Food and Drug Administration approval in May.

Persons: Moderna Organizations: Moderna, Pfizer, CNBC, subvariants, Food, Drug Locations: U.S, Canada, Covid

☆ Amgen wants in on the booming weight loss drug market — and it's taking a different approach
▼ + stars: | 2024-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S

☆ General Electric is among the most overbought names on Wall Street. Here are the others
▼ + stars: | 2024-03-22 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

After significantly outperforming the broader market this year, shares of General Electric could see a pullback, at least according to one popular chart metric. Using the CNBC Pro Stock Screener tool, we searched for the most overbought and oversold names in the S & P 500 based on their 14-day relative strength index, or RSI. Here are some of the most overbought names: General Electric 's 14-day RSI of nearly 83 indicates that shares could be overbought. Several oil and gas names are also overbought, according to their RSI. However, Wall Street anticipates nearly 17% upside for Marathon Oil, according to LSEG.

Persons: LSEG, Wells, Roger Read Organizations: General, Federal Reserve, Dow Jones, Nasdaq, CNBC, Stock, GE, GE Vernova, New York Stock Exchange, Valero Energy, Marathon Petroleum, Marathon, NRG Energy, LSEG, NRG, Valero, Oil, Pfizer Locations: U.S, LSEG, Wells Fargo

☆ This overlooked corner of women's health could be a $350 billion market opportunity
▼ + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.

Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo

☆ How a boutique bank that rode last year's healthcare M&A streak into the big leagues plans to continue to compete with the JPMorgan's of the world
▼ + stars: | 2024-03-13 | by ( Reed Alexander | ) www.businessinsider.com time to read: +9 min

It was more than double the value of the next-largest deal, a Japanese healthcare merger that clocked in at $22 billion. And, for its part, Seagen tapped advisors at two boutique firms: Centerview and MTS Health Partners. "We want to be the preeminent healthcare bank. Last year, during a healthcare M&A boom that's expected to continue this year, the bank onboarded 14 new staffers, including the partners, a company spokesperson said. Advertisement"We are absolutely in growth mode looking to have high-quality bankers who are capable of generating business off of this platform without all the accoutrements of a big bank," Weisenfeld continued.

Persons: Seagen, Andrew Weisenfeld, Goldman Sachs, Morgan Stanley, Dealogic, Weisenfeld, —, Curtis Lane, Bear, Daun Chung, Ryan Stewart, Reed Alexander Organizations: Service, Pfizer, Guggenheim, Centerview, MTS Health Partners, MTS, Goldman, JPMorgan, Bank of America, Partners, CTI, New, Bear Stearns, London Stock Exchange, Seagen, Medicines, Novartis, Chase Securities, Health Partners, Guggenheim Securities, Triple, SVB Securities, Solomon Partners, Citigroup Locations: Wall, New York City, Seattle

☆ Robert Kennedy Jr. says he's seriously considering Jets QB Aaron Rodgers to be his running mate
▼ + stars: | 2024-03-12 | by ( Brent D. Griffiths | ) www.businessinsider.com time to read: +2 min

According to The New York Times, Kennedy has talked to Jets QB Aaron Rodgers. AdvertisementLongshot presidential hopeful Robert Kennedy Jr. told The New York Times that he is considering both Jets quarterback Aaron Rodgers and former Minnesota Gov. Per the Times, Rodgers has welcomed Kennedy's interest, and someone registered the domain kennedyrodgers.com last week. The former NFL MVP is still under contract with The New York Jets. As the Times noted, Kennedy must name a running mate relatively soon to comply with state ballot access deadlines.

Persons: Kennedy, Aaron Rodgers, Jesse Ventura, —, Robert Kennedy Jr, Joe Biden, Ventura, Rodgers, Andrew Yang, Tulsi Gabbard, Sen, Rand Paul, Travis Kelce, Anthony Fauci, Jimmy Kimmel, Jeffrey Epstein, Kimmel, Epstein Organizations: RFK Jr, The New York Times, Minnesota Gov, Service, New York Times, Jets, Rodgers, Times, NFL, The New York Jets, Green Bay Packers, Democratic, Kentucky Republican, Chiefs, Pfizer Locations: Kentucky

☆ Final Trades: Pfizer, D.R. Horton, Progressive and Alphabet
▼ + stars: | 2024-03-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Pfizer, D.R. Horton, Progressive and AlphabetThe Investment Committee shares their top stocks to watch for the second half.

Organizations: Pfizer, D.R, The, Committee Locations: Horton

☆ CNBC Daily Open: A mixed picture on U.S. jobs growth
▼ + stars: | 2024-03-11 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. U.S. stocks retreatWall Street finished Friday's session lower as investors look ahead to key inflation data due out this week. Japan skirts technical recessionJapan avoided a technical recession as revised fourth-quarter data revealed the economy returned to growth. "My famous topless sports massage was all about showing our culture, to be honest, that we had such a flexible culture," the Malaysian businessman told CNBC.

Persons: Tony Fernandes, Tasha Keeney Organizations: Grand Central Market, CNBC, Wall, Nasdaq, Dow, Gross, AirAsia, Pfizer Locations: Los Angeles , California, U.S, Japan, Malaysian

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ OpenAI announces 'improvements' to its governance structure nearly 5 months after Sam Altman's ouster
▼ + stars: | 2024-03-09 | by ( Erin Snodgrass | Lloyd Lee | ) www.businessinsider.com time to read: +4 min

OpenAI announced Friday that it was adding three women to its board of directors. CEO Sam Altman is also rejoining the board nearly five months after he was abruptly forced out. The company has pledged to improve its governing structure in the aftermath of the ouster and reinstatement. A Thursday report from The New York Times suggested OpenAI chief technology officer Mira Murati raised concerns about Altman's leadership with board members prior to his removal. The three women join current OpenAI board members Adam D'Angelo, Larry Summers, and Bret Taylor, as well as Altman.

Persons: OpenAI, Sam Altman, —, Altman, Mira Murati, Murati, James, Sue Desmond, Hellmann, Melinda Gates, Nicole Seligman, Fidij Simo, Desmond, Seligman, Simo, Adam D'Angelo, Larry Summers, Bret Taylor Organizations: Service, The New York Times, OpenAI, University of California, Times, Melinda Gates Foundation, Global, Sony, Pfizer, Advisors, Science, Technology, Paramount Global, Meira, Inc Locations: Los Angeles, President's, Shopify

☆ Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7
▼ + stars: | 2024-03-08 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at pharma companies' surging stocks and threatening tech darlings thanks to their weight-loss drugs. And it comes despite only 1% of US adults taking weight-loss drugs, according to Bank of America , which predicts that number could rise to 15% by 2035. Weight-loss drugs are also cutting more than just fat. For Wall Street, meanwhile, the equation is much simpler: Getting more people on weight-loss drugs boosts the economy. The trend, which will be powered by cash-rich mega-cap tech companies, is thanks to strong earnings growth, the bank said.

Persons: —, Joe Biden, Donald Trump —, Trump, Zhan, Eli Lilly, Tesla, Hannah Latham, Octavio Jones, Christian Rodriguez, Laura MacPherson, Jenny Chang, Rodriguez, they're, Goldman Sachs, Biden, Barry Sternlicht, Fernando Gutierrez, It's, Elon Musk, TikTok, Pete Ryan, RJ Scaringe, Dan DeFrancesco, Hallam Bullock, Jordan Parker Erb, George Glover Organizations: Service, pharma, Business, Tesla, Microsoft, JPMorgan, Pfizer, Novo Nordisk, Bank of America, Nvidia, Companies, Fed, Infrastructure Investment, Alpha, Commission, Elon, EV, Nike, Congress, White, Meta, SXSW Locations: China, US, New York, London

☆ EVs are eventually the way of the future, says MAI Capital's Chris Grisanti
▼ + stars: | 2024-03-08 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEVs are eventually the way of the future, says MAI Capital's Chris GrisantiChris Grisanti, MAI Capital Management chief equity strategist, joins 'The Exchange' to discuss how to trade Hersehy, Pfizer, Bristol Myers, Albemarle, and homebuilders.

Persons: Chris Grisanti Chris Grisanti, Bristol Organizations: MAI Capital Management, Pfizer Locations: Bristol Myers, Albemarle

☆ Sam Altman rejoins OpenAI board of directors as investigation into his ouster comes to a close
▼ + stars: | 2024-03-08 | by ( Hayden Field | ) www.cnbc.com time to read: +7 min

Sam Altman, CEO of OpenAI, attends the 54th annual meeting of the World Economic Forum, in Davos, Switzerland, on Jan. 18, 2024. OpenAI on Friday announced its new board and the wrap-up of an internal investigation by U.S. law firm WilmerHale into the events leading up to OpenAI CEO Sam Altman's ouster. Sam Altman will also rejoin OpenAI's board. "We have unanimously concluded that Sam and Greg are the right leaders for OpenAI," Bret Taylor, chair of OpenAI's board, said in a release. Since then, OpenAI has announced new board members, including former Salesforce co-CEO Bret Taylor and former Treasury Secretary Larry Summers.

Persons: Sam Altman, OpenAI, WilmerHale, Sam Altman's, OpenAI's, Sue Desmond, Hellmann, Melinda Gates, Nicole Seligman, Fidji Simo, Adam D'Angelo, Larry Summers, Bret Taylor, Greg, Sam, Taylor, Altman, Bret, Larry, Mira Murati, Mira, Helen Toner, Tasha McCauley, Ilya Sutskever, Ilya, Elon Musk, Greg Brockman, Musk, –, Toner, McCauley, Altman's Organizations: Economic, Friday, Melinda Gates Foundation, Pfizer, Advisors, Science, Technology, Global, Sony, Sony Entertainment, Paramount Global, Meira, Inc, Shopify, OpenAI, Microsoft, Fortune, Lawyers, CNBC, SpaceX, Nvidia Locations: Davos, Switzerland, President's, OpenAI's San Francisco, U.S, Saudi Aramco

NEW YORK (AP) — A federal judge in Texas has ordered a 55-year-old U.S. agency that caters to minority-owned businesses to serve people regardless of race, siding with white business owners who claimed the program discriminated against them. The agency, which helps minority-owned businesses obtain financing and government contracts, now operates in 33 states and Puerto Rico. Justice Department lawyers representing Minority Business Development Agency declined to comment on the ruling, which can be appealed to the conservative-leaning 5th U.S. John F. Robinson, president of the National Minority Business Council, said the ruling is “a blow against minority owned businesses," and does nothing to help majority-owned businesses because they already enjoy access to federal resources through the Small Business Administration. "It has the potential of damaging the whole minority business sector because there will be less service available to minority-owned businesses,” Robinson said.

Persons: Mark T, Pittman, Donald Trump, Nixon, Biden, ” Pittman, Dan Lennington, ” Lennington, John F, Robinson, ” Robinson, Arian Simone, Alphonso David, David, Stanley Goldfarb, ”, “, —, David Glasgow, Graham Lee Brewer, Haleluya Hadero Organizations: —, U.S, Northern, Northern District of, U.S . Commerce Department, Infrastructure Investment, Jobs, Black, Wisconsin Institute for Law & Liberty, Justice Department, Business, Agency, Circuit, National Minority Business Council, Small Business Administration, Economic, Pfizer, The, Appeals, American Alliance for Equal Rights, Meltzer Center for Diversity, New York University’s School of Law, Supreme, AP Locations: Texas, Northern District, Northern District of Texas, Puerto Rico, New Orleans, Tennessee, Atlanta, The New York, Florida, New

☆ A man deliberately got 217 Covid shots. Here’s what happened
▼ + stars: | 2024-03-06 | by ( Mira Cheng | ) edition.cnn.com time to read: +7 min

The man, who is not named in the correspondence in compliance with German privacy rules, reported receiving 217 Covid shots between June 2021 and November 2023. Raising suspicionsAccording to his immunization history, the man got his first Covid vaccine in June 2021. The adaptive immune system is the subsection of the immune system that learns to recognize and respond to specific pathogens when you encounter them throughout your life, Miller said. Last week, the CDC updated its guidance to recommend an additional dose of the current Covid vaccine for people 65 and older. Less than a quarter of adults and only 13% of children in the US have gotten the most recently recommended Covid vaccine, according to CDC data.

Persons: hypervaccination ”, ”, Emily Happy Miller, ” Miller, “, Dr, Kilian Schober, Friedrich, hypervaccination, ” Schober, Schober, Miller, Hypervaccination, that’s, Johnson, Sanjay Gupta Organizations: CNN, Albert Einstein College of Medicine, Alexander University Erlangen, Red Cross, RTL, Pfizer, Moderna, Johnson, Sanofi, CNN Health, Centers for Disease Control, CDC Locations: Magdeburg, Nürnberg, Saxony, Dresden, Eilenburg, United States

☆ This move could help protect your portfolio from volatility as stocks trade near their highs
▼ + stars: | 2024-03-05 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +5 min

There's a party happening in stocks in 2024, and though investors may be reluctant, it could be time to think of taking a few chips off the table. My portfolio has recovered [from 2022],'" said Marguerita Cheng, certified financial planner and CEO of Blue Ocean Global Wealth in Gaithersburg, Maryland. "I tell people we're not selling everything, but we need to give the portfolio the TLC it deserves – this is the fine-tuning of your portfolio," she added. Be tax aware: Investors may be wary of selling highly appreciated holdings within their taxable accounts, which can incur levies on capital gains. Cheng of Blue Ocean has been turning toward dividend payers, as well as small and midcap stocks.

Persons: There's, they're, Marguerita Cheng, it's, Morningstar, Carla Adams, –, Sean Lovison, Cheng, Russell, Matson, – that's, It's, Jon Ulin Organizations: Nasdaq, Dow Jones, Netflix, Blue, Global Wealth, CNBC's, CFP, Ametrine, Investors, redeploy, Pfizer, Micron Technology, Holdings, Federal Reserve, Ulin, Wealth Management Locations: Gaithersburg , Maryland, Lake Orion , Michigan, Moorestown , New Jersey, SDVY, Boise, Boca Raton , Florida

☆ Trade Tracker: Josh Brown buys more Pfizer
▼ + stars: | 2024-03-05 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Josh Brown buys more PfizerJosh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he believes Pfizer is one of the best opportunities in the market right now.

Persons: Josh Brown, Pfizer Josh Brown Organizations: Pfizer, Ritholtz Wealth Management

Search resuls for: "Pfizer"

25 mentions found